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315Abstracts
non-medical costs (i.e., physician visits, hospitalizations, and
special nurses/caregivers) were retrieved from a private hospital
in Thailand. Effectiveness was deﬁned as the improvement of 
the Alzheimer’s disease assessment scale-cognitive subscale
(ADAS-cog) scores. Effectiveness data and probabilities used in
the model were obtained from relevant published studies. Sensi-
tivity analyses were performed to determine the model robust-
ness. RESULTS: The cost-effectiveness analyses shows that
compared with no treatment, incremental cost of high dose-
rivastigmine costs the lowest for patients with Alzheimer’s
Disease to gain one point improvement of ADAS-cog score
[30,162 Baht ($754) per year], whereas the incremental cost of
donepezil was 32,362 ($809) Baht per year and low dose-
rivastigmine costs the highest [77,102 ($1928) Baht per year].
Sensitivity analyses shows that the model is robust. CONCLU-
SION: High dose-rivastigmine and donepezil are more cost-
effective compared with low dose-rivastigmine for patients with
Alzheimer’s Disease in Thailand.
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OBJECTIVE: Quetiapine has been shown to be effective in the
treatment of behavioral and psychological signs of dementia
(BPSD). This analysis evaluates the cost-effectiveness of treating
community-dwelling patients with Alzheimer’s disease (AD) and
BPSD in the US. METHODS: A discrete event simulation was
designed to track the symptoms of BPSD and the resulting inﬂu-
ence on costs, caregiver burden and institutionalization in indi-
viduals under two scenarios: treatment with quetiapine at 200
mg per day, and no treatment. The model is populated using data
from a randomized trial comparing quetiapine to placebo, a lon-
gitudinal cohort study in AD patients, US costing sources, and
the literature. Costs, reported in 2004 US dollars, are examined
from the perspective of a comprehensive health care payer and
society, and include doctor visits, nursing home stays, hospital-
ization, adult day care, home health care, caregiver time and que-
tiapine treatment. In the base case, a one year time horizon is
used. RESULTS: On average, untreated patients spend just over
60% of their time in the community with high levels of BPSD,
while caregivers spend an average of 5.7 hours per day caring
for patients. Per patient costs average $35,642, 77% of which
consists of informal caregiving costs. Quetiapine reduces the time
spent with high BPSD by 24 days, while caregiver time is reduced
by 76 hours per patient. A modest reduction in institutionaliza-
tion (9%) is also predicted. The net effect is an increase in direct
costs of $439 per patient ($6830 per high BPSD year avoided),
but savings of $738 from the societal perspective. A total of 96%
of replications resulted in quetiapine dominating no treatment
from the societal perspective. Results are particularly sensitive to
caregiver time valuation. CONCLUSIONS: Treatment with que-
tiapine has the potential to alleviate caregiver burden and can
lead to considerable savings from the societal perspective.
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OBJECTIVES: To identify changes in management levels and
costs for a cohort of nursing home residents admitted for
Alzheimer’s disease (AD) over a six-year period. METHODS:
Long-term care data from Minnesota for 1995 through 2000
were examined. Nurses from Minnesota’s Quality Assurance and
Review Program evaluate care needs of nursing home residents
annually. Residents are classiﬁed according to dependence level
in each of eight activities of daily living (ADL). This ADL assess-
ment and other factors establish the management level and reim-
bursement rate for care. AD cases were identiﬁed using ICD-9
principal diagnosis codes and personal identiﬁers. Only patients
with AD who were residents throughout the six years were 
analyzed. Nursing home reimbursement rates for 2002 were
obtained from Minnesota’s Department of Human Services. Cost
estimates include nursing and ancillary staff care, and room and
board. Costs are reported in 2002 US$. RESULTS: Of the 2382
assessed patients with AD identiﬁed in 1995, 382 qualiﬁed for
this analysis. Of those, 90% were female and the mean age was
81 years (range: 56–101). Behavior problems were noted in 71%
in 1995 and 2000. In 1995, 25% received an antipsychotic agent
regularly. This rate decreased each year and was 15% by 2000.
The proportion of residents in low and medium dependency
levels decreased from 59% to 16% over six years; whereas, the
high dependency group rose from 41% to 84%. In 2000, sig-
niﬁcantly (p = 0.000) more residents were assessed as physically
and mentally incapable of self-preservation than in 1995. On
average, this increase in care needs resulted in an additional
annual cost of $7273 per resident by the end of the six-year
period and roughly $2.6 million for the cohort. CONCLU-
SIONS: Patients with AD residing in nursing homes continue to
deteriorate over time, resulting in a substantial increase in care
needs and costs.
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OBJECTIVE: To examine the persistency rates and persistency
days of rivastigmine and donepezil in patients with Alzheimer’s
Disease (AD) and to determine predictors of persistency.
METHODS: This retrospective study used MarketScan®
research database during January 1, 1999–December 31, 2002.
The study identiﬁed 229 new users of rivastigmine and 554 new
users of donepezil (i.e., no use of cholinesterase inhibitor (ChEI)
during the 18 month-history period) who were newly diagnosed
with AD between July 1, 2000–June 30, 2001, were at least 65
years old, and had continuous health/prescription insurance.
Patients who reﬁlled their initial ChEI prescription within a per-
missible gap of 60 days after depleting the drug supply from 
the prior prescription were considered to be persistent and the
robustness of the persistency deﬁnition was tested using sensi-
tivity analysis. Kaplan-Meier method and Cox proportional
hazard models were performed to examine the trends of persis-
tency and to identify factors that signiﬁcantly inﬂuenced persis-
tency. RESULTS: During the 1-year follow-up period, 53% of
rivastigmine and donepezil users discontinued or switched their
medications. Discontinuation was more common in donepezil-
users (43%) than in rivastigmine-users (37%), but switching
occurred more frequently in rivastigmine users (16% vs. 10%).
Rivastigmine-users continuously used their medication for an
average of 234 days while donepezil-users for 235 days (p =
0.91). Results were stable with variations in the deﬁnition of con-
